Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival
Author:
Publisher
Wiley
Subject
Biochemistry (medical),Clinical Biochemistry,Hematology,General Medicine
Reference8 articles.
1. The position of the M-BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukaemia
2. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
3. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy
4. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An unusually long survival without stem cell transplantation after the blast crisis phase of chronic myeloid leukemia: A case report;Leukemia Research;2012-01
2. A case report of a 33-year chronic phase survivor of chronic myeloid leukemia;Medical Oncology;2011-02-27
3. Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment;Leukemia Research;2010-02
4. Uncommon long-term survival in a patient with chronic myeloid leukemia;Acta Oncologica;2009-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3